Recent News for NK - NantKwest, Inc.

Date Title
Oct 2 Does NantKwest, Inc.'s (NASDAQ:NK) CEO Pay Reflect Performance?
Aug 27 Who Has Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
Aug 23 NantKwest files for $300M mixed shelf
Jul 31 DelMar Pharmaceuticals leads healthcare gainers; Lexicon Pharmaceuticals and T2 Biosystems among losers
Jul 12 NantKwest: Continues To Sell Off Despite The Clinical Progress
Jul 11 Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?
Jun 24 NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
Jun 6 Cheryl Cohen Appointed to NantKwest’s Board of Directors
Jun 4 CEL-SCI and BIOLASE among healthcare gainers; Navidea Biopharmaceuticals leads the losers
Jun 4 NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
Jun 4 NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
Jun 3 NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
Jun 3 NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
May 31 NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
May 23 What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?
May 1 Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
Back to the Main NK Page...